PP
RPRX

PDT Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

PDT Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-33,762
Closed -$251K – 1313
2015
Q3 		$251K Sell
33,762
-37,746
-53% -$289K 0.01% 1097
2015
Q2 		$511K Buy
71,508
+600
+0.8% +$4.67K 0.01% 970
2015
Q1 		$609K Sell
70,908
-797
-1% -$7.13K 0.02% 947
2014
Q4 		$715K Sell
71,705
-28,416
-28% -$242K 0.07% 399
2014
Q3 		$991K Buy
100,121
+73,916
+282% +$1.09M 0.03% 656
2014
Q2 		$453K Buy
+26,205
New +$427K 0.01% 1055
2013
Q4 		– Sell
-103,945
Closed -$2.79M – 1545
2013
Q3 		$2.79M Buy
+103,945
New +$2.23M 0.08% 361

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

PDT Partners's RPRX Position: Q4 2015 in Review

PDT Partners sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 33,762 shares — an estimated $251K sold.

PDT Partners first reported a position in RPRX in Q3 2013 and held it in 7 quarters. The position peaked at $2.79M in Q3 2013. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

  • PDT Partners reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • PDT Partners sold 33,762 Repros Therapeutics Inc. shares in Q4 2015, an estimated $251K.
  • PDT Partners first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 7 quarters.
  • PDT Partners's Repros Therapeutics Inc. position peaked at $2.79M in Q3 2013.
  • 56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on PDT Partners's 13F filing for Q4 2015, filed 16 Feb 2016.